Statement: the primary trial and the secondary trial have no overlap in the drugs they use for their interventions.
Primary_evidence: INTERVENTION 1:    Stratum 1: TAC + Bevacizumab   HER2 negative participants were administered chemotherapy with docetaxel, doxorubicin and cyclosphosphamide (TAC) + bevacizumab every 3 weeks for 6 cycles, and maintenance therapy with bevacizumab every 3 weeks for a total of 52 weeks. INTERVENTION 2:    Stratum 2: TCH + Bevacizumab   HER2 positive participants were administered chemotherapy with docetaxel, carboplatin and trastuzumab (TCH) + bevacizumab every 3 weeks for 6 cycles, and maintenance therapy with bevacizumab and trastuzumab every 3 weeks for a total of 52 weeks.
Secondary_evidence: INTERVENTION 1:    Triptorelin Plus Tamoxifen   Determination of estrogen levels in blood samples from patients being treated with triptorelin plus tamoxifen for 5 years. INTERVENTION 2:    Triptorelin Plus Exemestane   Determination of estrogen levels in blood samples from patients being treated with triptorelin plus exemestane for 5 years.